Clinical Data Major trial launched to explore GLP-1 benefit in dementia PharmaphorumA $100m trial has been launched to see if lifestyle changes coupled with GLP-1 agonists or similar incretins can reduce the risk of dementia.NeuroscienceRead full story pharminent July 13, 2026 (Last updated: July 14, 2026) Pharmaphorum A $100m trial has been launched to see if lifestyle changes coupled with GLP-1 agonists or similar incretins can reduce the risk of dementia. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA posts new rejection letters days after confirming pauseNext: Germany approves healthcare costs overhaul despite significant pharma opposition Related Stories Clinical Data Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs pharminent July 14, 2026 Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026
